Further, E6AP can suppress the metastasis suppressor n-Myc downstream regulated 1 (NDRG1) in mesenchymal phenotypes of prostate cancer where stabilization of NDRG1, via pharmacological inhibition of E6AP, has been proposed for prostate cancer therapy [56]. The gene discussed is UBE3A; the disease is prostate cancer.